Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Promising new treatment options for prostate cancer

Prostate cancer is the second leading cause of death among American men. It is estimated that one in six males will develop the disease during his lifetime. However, promising new treatment options have been developed to help combat this threatening disease.

9 Oct 2005

First human trials start in Canada for muscle-derived stem cells as a treatment for urinary incontinence

Human muscle-derived cells, pluripotent stem cells found in muscle, have been used to cure stress urinary incontinence in animal models, a finding which signals that these cells are prime candidates to treat the condition in adults.

31 Aug 2005

Episiotomies still common despite global recommendations to restrict use

Episiotomy is often called the unkindest cut of all. The procedure involves cutting the skin and muscles of the perineal area, the tissue between a woman's vagina and anus, while she is giving birth. It was once thought to be less painful and damaging than allowing the tissue to tear naturally.

30 Aug 2005

Minimally invasive prostate removal aided by a robot has possible benefits, high cost

Although minimally invasive prostate removal aided by a robot can lead to less blood loss, shorter hospital stays and fewer complications, there is no evidence that the procedure improves cure rates, according to a new technology assessment.

29 Aug 2005

Physiotherapy is effective in treating stress incontinence

Physiotherapy is effective in treating stress incontinence in about 80 per cent of cases, according to the first national study undertaken in clinical practice by researchers at the University of South Australia.

20 May 2005

Episiotomy usually provides no benefits

According to a systematic review of existing studies, to appear in the May 4 issue of the Journal of the American Medical Association, the surgical procedure known as an episiotomy, performed in up to 35 percent of U.S. vaginal births, usually provides no benefits.

5 May 2005

cT3 prostate cancer is operable

New findings from Mayo Clinic indicate that cT3 prostate cancer, a disease in which the cancer has spread locally from inside the prostate to immediately outside it, is operable and has 15-year cancer survival rates of almost 80 percent.

3 Apr 2005

Social and cultural factors play a significant role in the treatment decisions of patients with prostate cancer

Marital status, high school education, and race/ethnicity may play a far greater role in patients' treatment decisions than previously believed.

28 Mar 2005

Important that menopause not viewed as a disease

An independent panel convened last week by the National Institutes of Health found that many women move through the menopausal transition with few disabling symptoms, and that it is important that menopause not be viewed as a disease.

28 Mar 2005

Increased risk of urinary incontinence with hormone therapy

Menopausal hormone therapy (MHT), consisting of oral estrogen plus progestin or estrogen alone, considered in the past as treatment for urinary incontinenc, was until recently, credited with many benefits well beyond the indications for symptomatic relief of hot flashes, night sweats, and vaginal dryness. One of the benefits of MHT was to improve the symptoms of urinary incontinence (UI), and it has often been prescribed to treat UI.

21 Feb 2005

Clinical trial planned for stem cell treatment for stress urinary incontinence

ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence.

24 Jan 2005

FDA approves Enablex for the treatment of overactive bladder

Novartis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Enablex® (darifenacin) extended-release tablets (7.5mg and 15mg) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.

22 Dec 2004

Researchers are successfully treating incontinent women with the patient's own muscle-derived stem cells

Austrian researchers are successfully treating incontinent women with the patient's own muscle-derived stem cells. The findings of the first clinical study of its kind were presented today at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2004

Urinary incontinence and abdominal pain are key symptoms of ovarian cancer

Results from an Olmsted Medical Center and Mayo Clinic study analyzing symptoms recorded in the medical records of ovarian cancer patients suggest ovarian cancer, long considered asymptomatic until late-stage cancer develops, does in fact have early symptoms, including urinary incontinence and abdominal pain.

18 Nov 2004

Urinary incontinence is passed down from mother to daughter

New research from the University of Bergen (UiB), Norway, shows that a woman who’s mother has urinary incontinence has a 30 percent greater chance for incontinence herself.

4 Nov 2004

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

The antidepressant Cymbalta (duloxetine HCl), a dual-reuptake inhibitor of serotonin and norepinephrine, 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression, according to 12-week data presented at the annual meeting of the American College of Rheumatology.

18 Oct 2004

Prostate cancer treatment leads to declines in sexual and urinary function

Treatment for prostate cancer leads to significant five-year declines in sexual and urinary function, according to a new study. However, general and other specific health-related quality of life factors, such as bowel function, are not affected.

27 Sep 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Yentreve available in Europe for treatment of stress urinary incontinence

Yentreve (duloxetine hydrochloride) is now available in certain European countries, giving women suffering from moderate to severe stress urinary incontinence (SUI) a pharmaceutical treatment option for the first time.

13 Sep 2004

Cymbalta approved for diabetic peripheral neuropathy pain

The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.

8 Sep 2004